We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · September 14, 2021

Efficacy, Safety, and Factors Associated With Disease Progression in Patients Receiving Trametinib + Dabrafenib

European Journal of Cancer


Additional Info

European Journal of Cancer
Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib
Eur. J. Cancer 2021 Sep 01;154(xx)57-65, P Saiag, C Robert, JJ Grob, L Mortier, O Dereure, C Lebbe, S Mansard, F Grange, EM Neidhardt, T Lesimple, L Machet, C Bedane, H Maillard, S Dalac-Rat, C Nardin, A Szenik, A Denden, C Dutriaux

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading